Cholecalciferol supplementation can modify the balance of CD4+ T-cell subsets, resulting in a significant decrease in Th17/Th1 ratio in female patients with HT compared to the placebo group, in line with the beneficial immunological effects described in Section 4.2 [185]. Here, CD4 is linked to hematocrit.